NCT04427072
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04427072
Title Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (GeoMETry-III)
Acronym GeoMETry-III
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: senior | adult
Covered Countries NLD | LTU | ITA | HUN | FRA | ESP | DEU | BRA | BGR | BEL

Facility Status City State Zip Country Details
Novartis Investigative Site Leuven 3000 Belgium Details
Novartis Investigative Site Barretos São Paulo 14784 400 Brazil Details
Novartis Investigative Site São Paulo São Paulo 01246 000 Brazil Details
Novartis Investigative Site São Paulo São Paulo 04014-002 Brazil Details
Novartis Investigative Site Pleven 5800 Bulgaria Details
Novartis Investigative Site Sofia 1303 Bulgaria Details
Novartis Investigative Site Sofia 1407 Bulgaria Details
Novartis Investigative Site Caen 14021 France Details
Novartis Investigative Site Paris 75231 France Details
Novartis Investigative Site Pierre-Bénite 69495 France Details
Novartis Investigative Site Gauting Bavaria 82131 Germany Details
Novartis Investigative Site Regensburg Bavaria 93053 Germany Details
Novartis Investigative Site Berlin 13125 Germany Details
Novartis Investigative Site Berlin 14165 Germany Details
Novartis Investigative Site Cologne 50937 Germany Details
Novartis Investigative Site Oldenburg 26121 Germany Details
Novartis Investigative Site Törökbálint Pest County 2045 Hungary Details
Novartis Investigative Site Budapest 1121 Hungary Details
Novartis Investigative Site Pune Maharashtra 411013 India Details
Novartis Investigative Site New Delhi National Capital Territory of Delhi 110076 India Details
Novartis Investigative Site Vellore Tamil Nadu 632 004 India Details
Novartis Investigative Site Milan MI 20162 Italy Details
Novartis Investigative Site Roma RM 00128 Italy Details
Novartis Investigative Site Vilnius LT-08660 Lithuania Details
Novartis Investigative Site Kuala Lumpur Kuala Lumpur 50586 Malaysia Details
Novartis Investigative Site Kuantan Pahang 25100 Malaysia Details
Novartis Investigative Site Pulau Pinang 10990 Malaysia Details
Novartis Investigative Site Nijmegen 6500HB Netherlands Details
Novartis Investigative Site Lisbon 1769 001 Portugal Details
Novartis Investigative Site Matosinhos Municipality 4454 513 Portugal Details
Novartis Investigative Site Nizhny Novgorod 603081 Russia Details
Novartis Investigative Site Omsk 644013 Russia Details
Novartis Investigative Site Pushkin Saint Petersburg 196603 Russia Details
Novartis Investigative Site Saint Petersburg 197022 Russia Details
Novartis Investigative Site Port Elizabeth Western Cape 6045 South Africa Details
Novartis Investigative Site Seoul 05505 South Korea Details
Novartis Investigative Site Málaga Andalusia 29010 Spain Details
Novartis Investigative Site Oviedo Principality of Asturias 33011 Spain Details
Novartis Investigative Site Madrid 28009 Spain Details
Novartis Investigative Site Valencia 46026 Spain Details
Novartis Investigative Site Songkhla Hat Yai 90110 Thailand Details
Novartis Investigative Site Bangkok 10700 Thailand Details
Novartis Investigative Site Hanoi 100000 Vietnam Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field